Biofarma (PRIVATE.BIOFARMA)

Overall impact
A (86)

Commentary

Biofarma is a leader for overall positive impact. With an 'A' rating of 85.6 for overall impact (97th percentile compared to all companies), Biofarma ranks 1st out of 33 industry peers, ahead of Zoetis, Adamas Pharmaceuticals, Ironwood Pharmaceuticals and 29 others. On top material causes for Biofarma's industry (Pharmaceuticals & Biotech), Biofarma performs well in Child and Maternal Health (96.0 score), Disaster Readiness and Effective Aid (83.3), Accountable Institutions (80.7) and 10 other causes where it received an 'A' score. Biofarma did not receive a 'D' or 'F' rating on any cause.
Impact
Cause PRIVATE.BIOFARMA
Peer rank
Overall impact

Log in to view this information

Impact trend

Change in rating for overall impact

Log in to view this information

Company
Founded
1945
Employees
747
Sector
Health Care
Industry
Pharmaceuticals
Sub-industry
Pharmaceuticals
SASB industry
Biotechnology & Pharmaceuticals
Headquarters
Turkey
Share classes
PRIVATE.BIOFARMA
Description
Manufacturer of pharmaceutical products in Turkey focused on men's and women's health. The company manufactures generic drugs for allergies and the nervous system as well as for infectious, cardiovascular, gastrointestinal, renal, respiratory and metabolic diseases enabling better health for men and women.
Material causes
Ethos considers the following causes material for Biofarma, based on its industry sub-industry Pharmaceuticals. Learn more about material causes in our methodology overview.

This information is subject to Ethos' Terms and Conditions, which you can find here.

This information may not be used for corporate financing purposes (including, without limitation, ESG-linked loans, credit facilities, securities or structured products), as a basis for any financial instruments or products (including, without limitation, passively managed funds and index-linked derivative securities) or other products or services, to verify or correct data in any other compilation of data or index, to create any derivative works, nor to create any other data or index (custom or otherwise), without Ethos' prior written permission.

By browsing this site you agree to our use of cookies. Read more.
We use cookies on this site to enhance your user experience. By continuing to browse the site, you are agreeing to our use of cookies. Give me more info.